Objectives
Acute sciatica is a frequent cause of emergency department (ED) visits and hospital admissions. We evaluated the potential national cost savings of using ultrasound-guided transgluteal sciatic nerve block (TGSNB) in patients with acute sciatica who would otherwise be admitted.
Methods
We performed a Monte Carlo simulation with 10,000 iterations to compare the costs of usual care versus TGSNB targeted to patients who would otherwise require admission. Model inputs included national ED visits for acute sciatica, pre-block admission rates, admission costs, and procedural costs. The primary outcomes were per-patient savings among admitted patients and projected annual national savings.
Results
Targeted use of TGSNB in admission-eligible patients yielded mean per-patient savings of $11,974 (95 % UI: $6702–$18,527). Extrapolated nationally, this corresponds to $45.8 M (95 % UI $22.9 M–$74.0 M) in annual savings. Block costs were modest ($0.67 M (95 % UI: $0.46 M–$0.93 M)), and sensitivity analysis identified admission rates and costs as the main drivers of savings.
Conclusions
Adoption of TGSNB for severe sciatica in the ED may reduce admissions and generate meaningful healthcare savings. Prospective studies are needed to confirm clinical efficacy and implementation feasibility.
Capsule Summary:
- 1.What is already known on this topic:Ultrasound-guided transgluteal sciatic nerve block (TGSNB) can rapidly relieve radicular pain; ED adoption is limited.
- 2.What question this study addressed:What national cost savings could result if EDs target TGSNB to patients with acute sciatica who would otherwise be admitted?
- 3.What this study adds to our knowledge:A Monte Carlo model (10,000 iterations) projects $11,974 per-treated-patient savings and $45.8 M annual national savings, with admission rate and admission cost as primary drivers.
- 4.How this is relevant to clinical practice:Targeted ED TGSNB could reduce admissions and overall costs while supporting opioid-sparing pain management.
扫码关注我们
求助内容:
应助结果提醒方式:
